Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT04320680
Recruiting Not applicable

Systemic Lupus Erythematosus Within the Framework of the Multidisciplinary Consultation

NCT04320680 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Brest
Phase
Not applicable
Started
2020-10-13
Last updated
2025-02-04

Condition(s) studied

Systemic Lupus Erythematosus

Investigational drug(s) / intervention(s)

description of a lupus patient cohort

description of a lupus patient cohort: description of a lupus patient cohort

Study summary

Diagnosis and follow up of a lupus cohort in a multidisciplinary consultation in Brest ( France)

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * women or men, more than 18 years old, coming to the multidisciplinary consultation in brest ( France). * With written consentment Exclusion Criteria: * patients less than 18 years old * refusing to participate * Under legal protection

Primary outcome measure(s)

  • Cohort lupus: epidemiologic lupus study about diagnosis and follow up — five years
    epidemiologic lupus study in collecting data ( description of the population, biologic and immunologic data collection, data of articular damges with xrays datas) about Diagnosis and follow up of a cohort lupus in a multidisciplibnary consultation in brest hospital ( France).

Trial sites (1)

FacilityCityRegionStatus
CHRU de Brest Brest France Recruiting

More University Hospital, Brest trials in France

Screening for Occult Malignancy in Patients With Unprovoked Venous Thromboembolism Active, not recruiting
Effectiveness and Safety of Early Intramuscular Botulinum Toxin Injections to Prevent Shoulder Deformity in Babies With Obstetrical Brachial Plexus Palsy Recruiting
Analgesic Effectiveness of Capsaicin 8% Cutaneous Patch in Children Recruiting
Impact on Quality of Life With Pulmonary RehAbilitation After Pulmonary eMBOlism: RAMBO Study Recruiting
Does the Therapist's Assessment of Movement Control in Low Back Pain Patients Correspond to an Objective Kinematic Modification Recruiting

Other trials for the same condition

Characterization of Autoreactive b Lymphocytes in Autoimmune Diseases and Immune Deficiencies Recruiting
A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus Active, not recruiting
Follow-up of the Systemic Lupus Erythematosus Cohort as Part of the Multidisciplinary Consultation at Brest CHRU Recruiting
A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus Recruiting
A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE) Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04320680 on ClinicalTrials.gov ↗ ← All trials in France